中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2014年
15期
2305-2306,2307
,共3页
冠状动脉疾病%瑞舒伐他汀%阿托伐他汀%内皮%血管%心脏功能试验
冠狀動脈疾病%瑞舒伐他汀%阿託伐他汀%內皮%血管%心髒功能試驗
관상동맥질병%서서벌타정%아탁벌타정%내피%혈관%심장공능시험
Coronary artery disease%Rosuvastatin%Atorvastatin%Endothelium%vascular%Heart function tests
目的:观察瑞舒伐他汀和阿托伐他汀对早发冠心病急性心肌梗死血管内皮及心脏功能影响,比较两种药物治疗早发冠心病的近期疗效。方法选择早发冠心病急性心肌梗死患者162例,应用随机数字表法分为A组和B组,每组81例。两组均给予心肌梗死常规治疗,A组同时给予瑞舒伐他汀10 mg/d;B组(同时给予阿托伐他汀20 mg/d,疗程均为6个月。结果治疗6个月后,两组总胆固醇( TC)、总甘油三酯( TG)、低密度脂蛋白胆固醇( LDL-C)、超敏C反应蛋白( hs-CRP)均显著降低,血流介导血管内皮舒张功能(FMD)、血清NO显著升高,差异均有统计学意义(t=2.573、2.487、2.422、2.556、3.223、3.175、2.583、2.542、3.528、3.107、3.506、2.982,均P<0.05);A组TC、LDL-C和hs-CRP显著低于B组(t=2.327、2.228、2.328,均P<0.05)。结论瑞舒伐他汀和阿托伐他汀他汀均可以降低早发冠心病急性心肌梗死患者血脂,减轻炎性反应并改善血管内皮功能,两者近期疗效相近,但瑞舒伐他汀具有更强的降脂和减轻炎症的功能。
目的:觀察瑞舒伐他汀和阿託伐他汀對早髮冠心病急性心肌梗死血管內皮及心髒功能影響,比較兩種藥物治療早髮冠心病的近期療效。方法選擇早髮冠心病急性心肌梗死患者162例,應用隨機數字錶法分為A組和B組,每組81例。兩組均給予心肌梗死常規治療,A組同時給予瑞舒伐他汀10 mg/d;B組(同時給予阿託伐他汀20 mg/d,療程均為6箇月。結果治療6箇月後,兩組總膽固醇( TC)、總甘油三酯( TG)、低密度脂蛋白膽固醇( LDL-C)、超敏C反應蛋白( hs-CRP)均顯著降低,血流介導血管內皮舒張功能(FMD)、血清NO顯著升高,差異均有統計學意義(t=2.573、2.487、2.422、2.556、3.223、3.175、2.583、2.542、3.528、3.107、3.506、2.982,均P<0.05);A組TC、LDL-C和hs-CRP顯著低于B組(t=2.327、2.228、2.328,均P<0.05)。結論瑞舒伐他汀和阿託伐他汀他汀均可以降低早髮冠心病急性心肌梗死患者血脂,減輕炎性反應併改善血管內皮功能,兩者近期療效相近,但瑞舒伐他汀具有更彊的降脂和減輕炎癥的功能。
목적:관찰서서벌타정화아탁벌타정대조발관심병급성심기경사혈관내피급심장공능영향,비교량충약물치료조발관심병적근기료효。방법선택조발관심병급성심기경사환자162례,응용수궤수자표법분위A조화B조,매조81례。량조균급여심기경사상규치료,A조동시급여서서벌타정10 mg/d;B조(동시급여아탁벌타정20 mg/d,료정균위6개월。결과치료6개월후,량조총담고순( TC)、총감유삼지( TG)、저밀도지단백담고순( LDL-C)、초민C반응단백( hs-CRP)균현저강저,혈류개도혈관내피서장공능(FMD)、혈청NO현저승고,차이균유통계학의의(t=2.573、2.487、2.422、2.556、3.223、3.175、2.583、2.542、3.528、3.107、3.506、2.982,균P<0.05);A조TC、LDL-C화hs-CRP현저저우B조(t=2.327、2.228、2.328,균P<0.05)。결론서서벌타정화아탁벌타정타정균가이강저조발관심병급성심기경사환자혈지,감경염성반응병개선혈관내피공능,량자근기료효상근,단서서벌타정구유경강적강지화감경염증적공능。
Objective To observe the effects of rosuvastatin and atorvastatin on vascular endothelial and car -diac function of patients with early acute myocardial infarction .Methods 162 patients with early acute myocardial infarction were selected and randomly divided into A group and B group by the digital table ,81 cases in each group . The two groups were given conventional treatment of myocardial infarction ,and A group was given rosuvastatin 10mg/d, and B group received atorvastatin 20mg/d,all the patients were treated for 6 months.Results After 6 months of treatment,the total cholesterol(TC),triglyceride(TG),low density lipoprotein(LDL-C),hs-CRP in two groups were significantly reduced,FMD,serum NO were increased,the differences were statistically significant (t=2.573,2.487, 2.422,2.556,3.223,3.175,2.583,2.542,3.528,3.107,3.506,2.982,all P<0.05).TC,LDL-C and hs-CRP in A group were significantly lower than those in B group (t=2.327,2.228,2.328,all P<0.05).Conclusion Rosuv-astatin and atorvastatin can reduce blood lipids in patients with premature coronary heart disease and acute myocardial infarction,reduce inflammation and improve endothelial function ,they have similar short-term efficacy,but rosuvastatin has stronger lipid-lowering effect and reducing inflammatory function .